APOA1 and focal segmental glomerulosclerosis: Therefore, in the present study, we aim to analyze the distribution of ApoA-I in kidney allograft biopsies of FSGS recurrent patients and determine whether it has the potential to be used as a diagnostic biomarker of FSGS relapse.